Patient anti-FVIII drug antibodies bind preferentially to a subset of FVIII covalent states
Abstract: Hemophilia A is a chronic life-threatening condition caused by the deficiency or dysfunction of plasma coagulation factor VIII (FVIII) and commonly managed by prophylaxis with regular infusion of FVIII protein. A major obstacle to FVIII replacement therapy is the generation of alloantibodi...
Saved in:
| Main Authors: | Diego Butera, Aster E. Pijning, Nathan G. Avery, Carmen H. Coxon, Clive Metcalfe, Angelina Mimoun, Sébastien Lacroix-Desmazes, Paul Clint Spiegel, Jr., Philip J. Hogg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2473952925002174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Synovial Gene expression after Hemarthrosis differs between FVIII-deficient mice treated with recombinant FVIII or FVIII-Fc Fusion Protein
by: Bilgimol Chumappumkal Joseph, et al.
Published: (2025-01-01) -
FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4
by: Mariarosaria Miranda, et al.
Published: (2024-12-01) -
Comparative Efficacy of Recombinant FVIII and Recombinant FVII Biosimilars in Severe Hemophilia A
by: Meganathan Kannan PhD, et al.
Published: (2025-03-01) -
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates
by: Himani Chand, et al.
Published: (2025-03-01) -
Correlation to FVIII:C in two thrombin generation tests: TGA-CAT and INNOVANCE ETP
by: Marcus Ljungkvist
Published: (2017-11-01)